# Everything you need to know about Amanta Healthcare IPO

**URL:** https://tradingqna.com/t/everything-you-need-to-know-about-amanta-healthcare-ipo/186079
**Category:** IPOs
**Created:** [August 29, 2025, 10:32am UTC](https://tradingqna.com/t/everything-you-need-to-know-about-amanta-healthcare-ipo/186079 "2025-08-29T10:32:03Z")
**Posts on this page:** 1
**Page:** 1

<div class="post-metadata">

### Author: ![hafzee](https://tradingqna.com/user_avatar/tradingqna.com/hafzee/32/29110_2.png) [@hafzee](https://tradingqna.com/u/hafzee)
#### Post date: [August 29, 2025, 10:32am UTC](https://tradingqna.com/t/everything-you-need-to-know-about-amanta-healthcare-ipo/186079/1 "2025-08-29T10:32:03Z")

</div>

### About

Amanta Healthcare is a pharmaceutical formulation manufacturer incorporated in 1994. The company specialises in sterile liquid formulations and operates across multiple therapeutic segments, including fluid therapy, respiratory care, ophthalmic, diluents, and irrigation solutions. Its manufacturing facility, located in Hariyala, Kheda district, Gujarat, is spread across over 66,000 square meters and is equipped with multiple LVP and SVP lines using ABFS and ISBM technologies. The company is WHO-GMP compliant and holds ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, and ISO 45001:2018 certifications.

### IPO schedule

| Issue open date | 2025-09-01 |
| --- | --- |
| Issue close date | 2025-09-03 |
| UPI mandate deadline | 2025-09-03 (5 PM) |
| Allotment finalization | 2025-09-04 |
| Refund initiation | 2025-09-08 |
| Share credit | 2025-09-08 |
| Listing date | 2025-09-09 |
| Mandate end date | 2025-09-18 |
| Lock-in end date for anchor investors (50%) | 2025-10-04 |
| Lock-in end date for anchor investors (remaining) | 2025-12-03 |

### Financials

| **Financial Year Ended** | **March 2023** | **March 2024** | **March 2025** |
| --- | --- | --- | --- |
| Total Assets | 374.06 | 352.11 | 381.76 |
| Revenue | 262.69 | 281.60 | 276.09 |
| Profit After Tax | -2.11 | 3.63 | 10.50 |

### Issue size

| **Funds Raised in the IPO** | **Amount** |
| --- | --- |
| Overall | ₹126 crores |
| Fresh Issue | ₹126 crores |

### Utilisation of proceeds

| **Purpose** | **INR crores (%)** |
| --- | --- |
| Capital expenditure for setting up a new manufacturing line of SteriPort | 70 (55.5%) |
| Capital expenditure for setting up a new manufacturing line for SVP | 30.13 (24%) |
| General corporate purposes | 25.87 (20.5%) |

### Strengths

- Established in 1994 with a diversified pharmaceutical product portfolio
- Advanced sterile liquid manufacturing across a wide volume range
- Certified facility with ISO, WHO-GMP, and advanced technologies
- Extensive domestic and global distribution and sales network
- Experienced leadership with a skilled, qualified employee base

### Risk factors

- High customer concentration poses revenue stability and dependency risks
- Delay in SteriPort/SVP expansion may impact growth plans
- Promoter guarantees tied to loans may affect operations
- Sterile liquid products carry serious product liability exposure
- Unsecured borrowings and personal guarantees increase financial vulnerability